XR-B
Phase 3Small molecule
XR-B is one of 9 small molecule programs targeting Buprenorphine. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Buprenorphine
#DrugCompanyPhaseTrials
1Suboxone
IIndivior Inc.
Approved
Buprenorphine/naloxone
AstellasPhase 3
Marinol
Jazz PharmaceuticalsPhase 3
Lucemyra
BBioCorRx Pharmaceuticals Inc
Phase 2
Epidiolex /ml
Jazz PharmaceuticalsPhase 3
XR-B
NNYU Langone Health
Phase 3
Isentress
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kaletra
GSKPreclinical
Buprenorphine Control
WWashington University School of Medicine
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for XR-B. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- NNYU Langone Health